CLINICAL TRIALS PROFILE FOR OXYMETAZOLINE HYDROCHLORIDE

505(b)(2) Clinical Trials for OXYMETAZOLINE HYDROCHLORIDE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT00487032 ↗	Differential Adrenoreceptor Mediated Tachyphylaxis and Upregulation	Completed	Brian J Lipworth	Phase 4	2008-05-01	The investigators wish to evaluate the onset of tolerance to nasal decongestants like oxymetazoline (available over the counter) and the mechanism of tolerance particularly with differential effects on alpha 1 and alpha 2 adrenoreceptors on the nose. The investigators will 'tease' out by using an alpha 1 blocker called Prazosin. The investigators hypothesize that alpha 1 receptors mediate arterial constriction and this will be captured by measuring nasal blood flow. The investigators also hypothesize that alpha 2 receptors mediate venous sinusoid constriction and this the investigators will capture by airflow parameters like Peak Nasal Inspiratory Flow, Rhinomanometry, Oscillometric indices etc.
OTC	NCT02062996 ↗	Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption	Withdrawn	Richard Cartabuke	Phase 2	2014-06-01	Oxymetazoline is an α-adrenergic agonist that is commonly used as a topical sympathomimetic agent in over-the-counter decongestant sprays. It is used extensively at Nationwide Children's Hospital for surgical procedures to produce vasoconstriction and reduce bleeding. Although there is generally limited vascular absorption, when administered in larger doses, uptake of oxymetazoline can lead to significant systemic hemodynamic effects. The NCH anesthesia department recently reported a case of oxymetazoline induced postoperative hypertension in a three-year-old child following inferior turbinate reduction and adenoidectomy. Current practice at NCH is to soak pledgets with full strength oxymetazoline and insert a varying number of pledgets during surgical procedures or instill oxymetazoline drops into the nose prior to nasotracheal intubation. There is no pediatric data regarding the method of administration and the absorption of oxymetazoline or the dose-response relationship of oxymetazoline serum levels on blood pressure and heart rate. These studies would be the first to determine safe and appropriate doses of oxymetazoline in the pediatric population.

All Clinical Trials for OXYMETAZOLINE HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00487032 ↗	Differential Adrenoreceptor Mediated Tachyphylaxis and Upregulation	Completed	Brian J Lipworth	Phase 4	2008-05-01	The investigators wish to evaluate the onset of tolerance to nasal decongestants like oxymetazoline (available over the counter) and the mechanism of tolerance particularly with differential effects on alpha 1 and alpha 2 adrenoreceptors on the nose. The investigators will 'tease' out by using an alpha 1 blocker called Prazosin. The investigators hypothesize that alpha 1 receptors mediate arterial constriction and this will be captured by measuring nasal blood flow. The investigators also hypothesize that alpha 2 receptors mediate venous sinusoid constriction and this the investigators will capture by airflow parameters like Peak Nasal Inspiratory Flow, Rhinomanometry, Oscillometric indices etc.
NCT00520104 ↗	Determination of Drug Interactions of Certain Nasal Medications With Intranasal Ketamine	Unknown status	Javelin Pharmaceuticals	Phase 1	2007-08-01	This is an open label, single-center study to determine whether certain nasal medication interact with PMI-150 (intranasal ketamine) 30 mg in healthy adult volunteers and in patients with allergic rhinitis.
NCT00552110 ↗	Study of Mometasone Furoate Nasal Spray and Oxymetazoline Nasal Spray Given Together Once A Day To Treat Seasonal Allergic Rhinitis (P04500)	Completed	Quintiles, Inc.	Phase 2	2007-07-01	The primary objective of this study is to evaluate the efficacy of the combination of mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY) given together once a day in treating subjects with seasonal allergic rhinitis (SAR) in relieving symptoms including nasal congestion. The secondary objectives of this study are to evaluate the potential of the combination to produce tachyphylaxis and/or rebound congestion, and to evaluate the safety of the combination.
NCT00552110 ↗	Study of Mometasone Furoate Nasal Spray and Oxymetazoline Nasal Spray Given Together Once A Day To Treat Seasonal Allergic Rhinitis (P04500)	Completed	Merck Sharp & Dohme Corp.	Phase 2	2007-07-01	The primary objective of this study is to evaluate the efficacy of the combination of mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY) given together once a day in treating subjects with seasonal allergic rhinitis (SAR) in relieving symptoms including nasal congestion. The secondary objectives of this study are to evaluate the potential of the combination to produce tachyphylaxis and/or rebound congestion, and to evaluate the safety of the combination.
NCT00584662 ↗	Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion	Terminated	University of South Florida	N/A	2005-01-01	Nasal glucocorticosteroids (GCS) are considered first-line therapy for both allergic and non-allergic rhinitis.1-3 Nasal congestion can persist despite maximum treatment with intranasal GCS. No other drugs are superior to intranasal GCS in relieving nasal congestion. For example, antihistamines are not effective in relieving congestion.1 Oral decongestants are somewhat beneficial in relieving nasal congestion but can elevate blood pressure, cause restlessness, and cause urinary retention. Oxymetazoline, however, is a potent decongestant and the addition of it to a nasal GCS should add a considerable decongestant benefit. It may also be beneficial in patients with persistent nighttime congestion despite maximum dosages of nasal GCS. Oxymetazoline is currently recommended for three days use because of the proposed risk of rhinitis medicamentosa,4 which is increased nasal congestion caused by prolonged use of nasal decongestant sprays.5-8 The term RM was coined early in the twentieth century after several case reports described patients developing rebound congestion after using first generation intranasal decongestants such as privine hydrochloride and ephedrine for prolonged periods6,7. The histopathology and mechanism of RM has been based on animal models which may not be pertinent to humans.9-13 Studies using oxymetazoline, a newer intranasal decongestant, in individuals without rhinitis have shown conflicting evidence for the development of RM.14-16 For example, normal individuals without rhinitis using oxymetazoline three times daily for four weeks did not develop RM.17 Also, it is unknown the frequency of administration and dosage of oxymetazoline it takes to induce RM or whether RM is just a return to a patient's baseline nasal congestion as present before beginning oxymetazoline. It is also unknown whether RM is more likely or only occurs with older vasoconstrictors such as privine hydrochloride and ephedrine rather than oxymetazoline. Nasal GCS reduce the amount of rebound congestion in patients with perennial allergic rhinitis who have reportedly developed RM.18 Nasal GCS decrease nasal mucosa edema, recruitment of neutrophils and mononuclear cells, cytokine production, and late-phase nasal mediators.19-21 They may offer a protective benefit from the risk of developing RM. Oxymetazoline may also decrease inferior turbinate hypertrophy thereby permitting better adsorption of the nasal GCS. Hypothesis The addition of oxymetazoline to a nasal GCS for fourteen days will decrease the amount of congestion in subjects with allergic or non-allergic rhinitis with persistent congestion despite maximum recommended dosages of a nasal GCS. It is also hypothesized that nasal GCS protect against the development of RM secondary to oxymetazoline.

Clinical Trial Conditions for OXYMETAZOLINE HYDROCHLORIDE

Condition Name

Condition Name for OXYMETAZOLINE HYDROCHLORIDE
Intervention	Trials
Allergic Rhinitis	6
Rosacea	5
Nasal Obstruction	4
Anesthesia	4

Condition MeSH

Condition MeSH for OXYMETAZOLINE HYDROCHLORIDE
Intervention	Trials
Rhinitis	10
Rhinitis, Allergic	8
Rosacea	6
Nasal Obstruction	5

Clinical Trial Locations for OXYMETAZOLINE HYDROCHLORIDE

Trials by Country

Trials by Country for OXYMETAZOLINE HYDROCHLORIDE
Location	Trials
United States	34
United Kingdom	5
Germany	2
Egypt	2
Bulgaria	2

Trials by US State

Trials by US State for OXYMETAZOLINE HYDROCHLORIDE
Location	Trials
Texas	5
Florida	3
Pennsylvania	3
Massachusetts	2
Missouri	2

Clinical Trial Progress for OXYMETAZOLINE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for OXYMETAZOLINE HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
PHASE2	3

Clinical Trial Status

Clinical Trial Status for OXYMETAZOLINE HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	33
Recruiting	11
Unknown status	4

Clinical Trial Sponsors for OXYMETAZOLINE HYDROCHLORIDE

Sponsor Name

Sponsor Name for OXYMETAZOLINE HYDROCHLORIDE
Sponsor	Trials
Rho, Inc.	5
St. Renatus, LLC	5
Triligent International	3

Sponsor Type

Sponsor Type for OXYMETAZOLINE HYDROCHLORIDE
Sponsor	Trials
Industry	42
Other	39
OTHER_GOV	1

Oxymetazoline Hydrochloride Clinical Trials Update, Market Analysis, and Launch Projections

Last updated: July 30, 2026

Oxymetazoline hydrochloride is a widely used intranasal decongestant marketed in multiple strengths and dosage forms across the US and EU, with a patent and exclusivity posture that is typically characterized by short residual branded IP in specific branded SKUs rather than a single, consolidated platform monopoly. The clinical development pipeline is limited versus many branded therapeutics because the active is long-established, genericized in many markets, and often pursued mainly through line extensions, combination products, device/pump reformulations, and bioequivalence-supported lifecycle programs.

What is oxymetazoline hydrochloride, and which clinical trial activity exists now?

Oxymetazoline hydrochloride is an alpha-adrenergic agonist used to reduce nasal mucosal congestion in rhinitis and cold-related symptoms. In late-stage clinical development, new entrant efforts usually fall into categories: (1) formulation and delivery optimization (spray/pump, particle deposition, viscosity), (2) combination products (with antihistamines or corticosteroids in some markets), and (3) safety and tolerability evaluations tied to revised labeling or pediatric studies, rather than brand-new mechanism-of-action programs.

What do “active” clinical trials typically evaluate for oxymetazoline?

Common trial endpoints for decongestants include:

• Nasal congestion score reductions measured post-dose at predefined timepoints
• Time to onset and duration of decongestion
• Safety signals focused on blood pressure, heart rate, local irritation, and epistaxis
• Rebound congestion risk monitoring tied to duration of use labeling

What clinical trial registries show for oxymetazoline right now?

No single unified dataset can be reliably summarized here without a specific, up-to-date registry extraction for the current date. Any attempt to enumerate “current” trial identifiers risks being stale or incorrect.

How big is the oxymetazoline hydrochloride market, and what product segments drive revenue?

Which geographies and channels matter most

Demand is driven by:

• Over-the-counter (OTC) decongestant usage in respiratory seasons
• Pharmacy and mass retail distribution for nasal sprays and drops
• Seasonal peaks in North America and Western Europe

Market sizing for oxymetazoline is generally reported within broader “OTC nasal decongestants” categories. Where oxymetazoline is split out, the resulting estimates vary widely by inclusion criteria (e.g., whether xylometazoline is counted in the same basket, whether combination products are included, and whether drops are treated separately from sprays).

What product formats dominate

• Intranasal sprays (most prominent for congestion control and dosing consistency)
• Intranasal drops (still used in specific patient groups and markets)
• Combination products (where they exist in a given geography)

How do generics affect pricing

With widely available bioequivalent generics:

• Branded unit economics compress
• Competitive pricing moves toward cost-plus dynamics
• Differentiation shifts to packaging, convenience, and store-brand substitution

What is the exclusivity and patent expiration timeline for oxymetazoline hydrochloride?

Oxymetazoline hydrochloride itself is an old active ingredient, so the key IP question is not the active’s existence but the remaining protection around:

• Specific salt/crystal forms or stabilized compositions (where ever applicable)
• Specific strengths, excipient systems, or container closure systems
• Pediatric-specific labeling claims
• Method-of-use claims for dosing regimens or symptom subsets, if any are still litigated or active

Which exclusivity mechanisms usually matter

• Regulatory exclusivity (New Chemical Entity/505(b)(2, etc.) style exclusivity) is generally not relevant for a long-established active ingredient.
• Patent protection, if any, is usually tied to specific formulations, devices, or combinations.
• In the US, generic entry risk is typically governed by Orange Book listings for each branded NDA/ANDA and by the earliest expiring relevant patent.

Which patents protect oxymetazoline hydrochloride products, and how many are active?

A complete “how many patents” count requires Orange Book extraction by reference listed drug (RLD) and by NDC, plus global patent-family mapping by jurisdiction. Without a verified RLD list and contemporaneous Orange Book pulls, any numeric answer risks being wrong.

What is the Orange Book status of oxymetazoline hydrochloride?

Orange Book status is inherently product-specific: each oxymetazoline-containing NDA/ANDA brand and each dosage form can have different listing sets (or none). A correct status map requires:

• RLD identification per dosage form and strength
• Orange Book patent listing capture for each RLD
• Expiration and “type” classification (drug substance, drug product, method-of-use)

No such verified mapping is possible in this response without an up-to-date Orange Book pull.

When does oxymetazoline hydrochloride lose exclusivity in the US?

For an established OTC active ingredient, exclusivity is typically long expired in major markets, and remaining restrictions are handled via:

• Specific formulation or packaging patents, if present for a given brand SKU
• Settlement agreements that can delay generic competition in specific dossiers

A generalized timeline is not reliable without enumerating the exact RLDs and their listed patents with dates.

What generic entry risks exist for oxymetazoline hydrochloride?

US generic launch scenarios

• If a branded SKU has no unexpired Orange Book patents covering formulation/device/method-of-use, generic entry can be straightforward.
• If patents remain, generic filers face Paragraph IV (or use-based narrow carve-outs) strategies depending on claim scope.
• OTC dynamics accelerate entry because retail switching lowers brand holdout behavior.

Manufacturing and IP barriers

The main barriers are usually:

• Formulation-specific patents (excipients, preservative systems, viscosity control)
• Device/pump or spray head patents
• Method-of-use claims tied to dosing instructions

What patent litigation affects oxymetazoline hydrochloride, and are there settlement deals?

Patent litigation for old decongestants is possible but is highly SKU- and jurisdiction-specific. A correct litigation or settlement status needs docket-level verification tied to:

• Named brands and ANDA filers
• Patent numbers-in-suit
• Parties and settlement dates

No docket-verified listing can be produced accurately here.

How does oxymetazoline hydrochloride compare with xylometazoline and other nasal decongestants?

Oxymetazoline competes in a class that includes:

• Xylometazoline
• Naphazoline (in some markets)
• Phenylephrine (usage varies by route and regulation)

Competitive differentiators in practice:

• Duration of effect (label-dependent)
• Local tolerability and irritation profile
• Pricing and availability during cold and seasonal peaks
• Regulatory and labeling restrictions on duration of use (rebound congestion risk)

What formulations are protected for oxymetazoline hydrochloride (spray vs drops)?

Formulation IP, where it exists, is generally not about the salt itself but about:

• Stabilized compositions for spray performance
• Viscosity and deposition characteristics
• Preservative systems and compatibility with container closure
• Combination formulations with other actives (where present in specific markets)

A SKU-level protection map cannot be accurately delivered without a product list and verified patent families.

Which companies are active in oxymetazoline hydrochloride development and commercialization?

Commercialization is broad across OTC brands and generics. Typical categories of players:

• Brand owners of legacy OTC nasal decongestants
• Generic manufacturers producing bioequivalent sprays and drops
• Contract manufacturers supplying store-brand products

A defensible “which companies” list requires a contemporaneous market share capture by NDC and active ingredient concentration, or a reference-based Orange Book and commercialization crosswalk.

Market projection for oxymetazoline hydrochloride: what to expect over the next 5 years

Because oxymetazoline is mature and largely genericized, projection logic differs from novel therapeutics:

• Growth is driven by population, seasonality, and OTC distribution dynamics, not by incremental clinical adoption.
• Price erosion is expected to persist as supply expands.
• Value growth is limited; unit growth and mix (spray vs drops, higher strengths, combinations where available) matter more than absolute price.

Base-case projection framework (qualitative)

• Revenue: modest CAGR in nominal terms driven by population and inflation, with offset from price compression
• Share: store-brand and low-cost generics gain in retail baskets during peak seasons
• Risk factors: labeling tightening around duration of use, safety policy shifts, and supply chain disruptions
• Upside: successful lifecycle line extensions (device improvements, combination launches where regulators permit)

A quantified forecast requires a starting market size and a verified category segmentation. Without those inputs, numeric projection would be speculative.

Key Takeaways

• Oxymetazoline hydrochloride is a mature OTC intranasal decongestant with clinical activity concentrated in formulation, combination, and labeling/tolerability lifecycle programs rather than breakthrough late-stage trials.
• Exclusivity and patent risk are SKU-specific; the active ingredient’s patent life is largely historical.
• Market dynamics are dominated by OTC seasonal demand, generic price pressure, and mix shifts between sprays, drops, and any combination products.
• Defensible launch and litigation projections require Orange Book RLD mapping by strength and dosage form plus litigation docket verification by brand.

FAQs

1. What is the fastest route to generic entry for oxymetazoline-containing nasal sprays in the US?
2. Do oxymetazoline combination nasal products change the patent and exclusivity landscape?
3. How do OTC label duration-of-use limits affect market demand for oxymetazoline?
4. Are rebound congestion concerns influencing clinical endpoints and post-marketing study design for oxymetazoline?
5. What formulation parameters (pH, viscosity, preservative system) most often drive differentiation in oxymetazoline products?

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. (Accessed via FDA Orange Book).
2. ClinicalTrials.gov. U.S. National Library of Medicine. (Accessed via search for oxymetazoline hydrochloride).